Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC.

Siobhan Halloran¹, Salman R Punekar², Mark Guinter³, Kelly Magee⁴, Michael S Ondovik⁵, J E Hamer-Maansson⁶, Mark J Cornfeld⁷, Doaa Ayoubi⁸, Mihaela C Munteanu⁹, Kim Saverno¹⁰

¹Flatiron Health, 233 Spring Street, New York, NY, 10013, USA. Electronic address: siobhan.halloran@flatiron.com.

²NYU Langone Health, 550 1st Avenue, New York, NY, 10016, USA. Electronic address: salman.punekar@nyulangone.org.

³Flatiron Health, 233 Spring Street, New York, NY, 10013, USA. Electronic address: mark.guinter@flatiron.com.

⁴Flatiron Health, 233 Spring Street, New York, NY, 10013, USA. Electronic address: kelly.magee@flatiron.com.

⁵Incyte Corporation, 1815 Augustine Cut Off, Wilmington, DE, 19803, USA. Electronic address: mondovik@incyte.com.

⁶Incyte Corporation, 1815 Augustine Cut Off, Wilmington, DE, 19803, USA. Electronic address: jhamermaansson@incyte.com.

⁷Incyte Corporation, 1815 Augustine Cut Off, Wilmington, DE, 19803, USA. Electronic address: mcornfeld@incyte.com.

⁸NYU Langone Health, 550 1st Avenue, New York, NY, 10016, USA. Electronic address: doaa.ayoubi@nyulangone.org.

⁹Incyte Corporation, 1815 Augustine Cut Off, Wilmington, DE, 19803, USA. Electronic address: mmunteanu@incyte.com.

¹⁰Incyte Corporation, 1815 Augustine Cut Off, Wilmington, DE, 19803, USA. Electronic address: ksaverno@incyte.com.

PubMed DOI

Abstract

BACKGROUND: Immunotherapies have improved survival in patients with metastatic non-small cell lung cancer (mNSCLC), yet a substantial fraction of eligible patients remain untreated with immunotherapy in routine clinical practice. This study examined treatment patterns and factors associated with receipt of non-immunotherapy-containing first-line (1L) regimens among patients with mNSCLC not eligibl…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.